



FOR IMMEDIATE RELEASE

Jounce Therapeutics to Present Program Updates at AACR Annual Meeting 2016

Cambridge, Mass., March 16, 2016 – Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment strategies, today announced that advances within the company’s immuno-oncology pipeline will be presented during two poster presentations on Sunday, April 17, 2016 at the American Association of Cancer Research (AACR) Annual Meeting 2016. The meeting is being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans.

The abstracts are now available on the AACR website. Jounce’s presentation details are as follows:

Title: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody

Abstract Code: 573

Poster Number: 4

Poster Session: PO.IM02.09 Therapeutic Antibodies

Date: Sunday, April 17, 2016

Session Time: 1:00-5:00p.m. ET

Location: Section 27

Title: Discovery of a novel TIM3 binding partner and a key role for TIM3 on macrophages: identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing

Abstract Number: 586

Poster Number: 17

Poster Session: PO.IM02.09 Therapeutic Antibodies

Date: Sunday, April 17, 2016

Session Time: 1:00-5:00p.m. ET

Location: Section 27

About Jounce Therapeutics

Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s translational science platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with



funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Media Contact:

Dan Budwick

Pure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com

###